Prediction of [¹⁷⁷Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [¹⁷⁷Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour.

ABSTRACT:

Background

Peptide receptor radionuclide therapy (PRRT) with [¹⁷⁷Lu]Lu-DOTA-TATE has shown efficacy in patients with metastatic neuroendocrine tumours (NETs). Personalised dosimetry is crucial to optimise treatment outcomes and minimise adverse events. In this study, we investigated the correlation between the tumour-absorbed dose (TAD) estimated from [¹⁷⁷Lu]Lu-DOTA-TATE SPECT/CT and the therapeutic response.

Method

A retrospective analysis was conducted on patients with advanced well-differentiated NETs grades 1-3 who underwent PRRT and exhibited greater uptake than liver on pre-therapeutic [⁶⁸Ga]Ga-DOTA-TOC PET/CT. Target lesions were selected based on the RECIST 1.1 and PERCIST 1.0 criteria using [¹⁷⁷Lu]Lu-DOTA-TATE SPECT/CT and

SUBMITTER: Ha S 

PROVIDER: S-EPMC10844176 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature